Science Advances :触发感染性休克的新分子信号

2017-05-04 MedSci medicalxpress

来自KAIST Seyun Kim的研究团队报道了细胞信号转导网络在调节先天免疫反应的过程中,如酶IPMK(肌醇多磷酸盐多激酶)对肌醇生物合成代谢的关键作用。  该研究与首尔国立大学的Rho Hyun Seong教授合作完成。文章第一作者、生物科学系的博士研究生尤妮哈·金(Eunha Kim)进行了一系列细胞、生化和生理学的实验,寻找巨噬细胞中IPMK酶的新功能。这项研究结果发表在4月21日的《科

来自KAIST Seyun Kim的研究团队报道了细胞信号转导网络在调节先天免疫反应的过程中,如酶IPMK(肌醇多磷酸盐多激酶)对肌醇生物合成代谢的关键作用。

该研究与首尔国立大学的Rho Hyun Seong教授合作完成。文章第一作者、生物科学系的博士研究生尤妮哈·金(Eunha Kim)进行了一系列细胞、生化和生理学的实验,寻找巨噬细胞中IPMK酶的新功能。这项研究结果发表在4月21日的《科学进展》上。

Kim教授的研究小组已经对各种肌醇代谢物和他们的生物合成代谢进行了几年的研究,并在细胞生长和能量平衡的控制中,对IPMK(肌醇多磷酸盐多激酶)的信号行为进行了多边识别。

该研究表明,当微生物脓毒性休克和内毒素激发时,巨噬细胞中IPMK酶的特异性缺失可显着降低小鼠的炎症水平并提高小鼠的存活率。这表明了IPMK酶在调节先天炎症反应中的作用,反应与宿主防御致病性细菌感染直接相关。

该小组进一步发现IPMK酶直接与TRAF6蛋白结合,TRAF6蛋白是免疫信号传导的关键蛋白,从而保护TRAF6蛋白免于参与蛋白质降解的泛素化反应。此外,Kim等人通过使用能够特异性干扰IPMK酶和TRAF6蛋白在巨噬细胞中结合的短肽,成功验证了IPMK依赖性免疫控制。

本研究揭示了IPMK酶在先天免疫信号网络微调中的一个新功能,提出了一种新的治疗方法,用于治疗严重的疾病,如神经炎症、2型糖尿病,以及由不受控制的宿主免疫反应产生的多菌败血症。研究获科技部、ICT和未来计划项目资助。

原文出处Eunha Kim et al, Inositol polyphosphate multikinase promotes Toll-like receptor–induced inflammation by stabilizing TRAF6, Science Advances (2017).

此文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=349588, encodeId=16993495882d, content=科研, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c4b1459687, createdName=fenfei_100, createdTime=Wed Oct 17 00:22:58 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923244, encodeId=80a0192324437, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Oct 28 12:28:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655377, encodeId=3b1416553e75c, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Nov 14 05:28:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207962, encodeId=80cc20e9629d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jun 08 05:23:59 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=202163, encodeId=34ee20216379, content=新信号通路发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed May 24 23:48:27 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375573, encodeId=6f0813e557331, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat May 06 13:28:00 CST 2017, time=2017-05-06, status=1, ipAttribution=)]
    2018-10-17 fenfei_100

    科研

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=349588, encodeId=16993495882d, content=科研, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c4b1459687, createdName=fenfei_100, createdTime=Wed Oct 17 00:22:58 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923244, encodeId=80a0192324437, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Oct 28 12:28:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655377, encodeId=3b1416553e75c, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Nov 14 05:28:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207962, encodeId=80cc20e9629d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jun 08 05:23:59 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=202163, encodeId=34ee20216379, content=新信号通路发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed May 24 23:48:27 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375573, encodeId=6f0813e557331, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat May 06 13:28:00 CST 2017, time=2017-05-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=349588, encodeId=16993495882d, content=科研, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c4b1459687, createdName=fenfei_100, createdTime=Wed Oct 17 00:22:58 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923244, encodeId=80a0192324437, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Oct 28 12:28:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655377, encodeId=3b1416553e75c, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Nov 14 05:28:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207962, encodeId=80cc20e9629d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jun 08 05:23:59 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=202163, encodeId=34ee20216379, content=新信号通路发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed May 24 23:48:27 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375573, encodeId=6f0813e557331, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat May 06 13:28:00 CST 2017, time=2017-05-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=349588, encodeId=16993495882d, content=科研, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c4b1459687, createdName=fenfei_100, createdTime=Wed Oct 17 00:22:58 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923244, encodeId=80a0192324437, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Oct 28 12:28:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655377, encodeId=3b1416553e75c, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Nov 14 05:28:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207962, encodeId=80cc20e9629d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jun 08 05:23:59 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=202163, encodeId=34ee20216379, content=新信号通路发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed May 24 23:48:27 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375573, encodeId=6f0813e557331, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat May 06 13:28:00 CST 2017, time=2017-05-06, status=1, ipAttribution=)]
    2017-06-08 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=349588, encodeId=16993495882d, content=科研, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c4b1459687, createdName=fenfei_100, createdTime=Wed Oct 17 00:22:58 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923244, encodeId=80a0192324437, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Oct 28 12:28:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655377, encodeId=3b1416553e75c, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Nov 14 05:28:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207962, encodeId=80cc20e9629d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jun 08 05:23:59 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=202163, encodeId=34ee20216379, content=新信号通路发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed May 24 23:48:27 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375573, encodeId=6f0813e557331, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat May 06 13:28:00 CST 2017, time=2017-05-06, status=1, ipAttribution=)]
    2017-05-24 惠映实验室

    新信号通路发现

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=349588, encodeId=16993495882d, content=科研, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c4b1459687, createdName=fenfei_100, createdTime=Wed Oct 17 00:22:58 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923244, encodeId=80a0192324437, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Oct 28 12:28:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655377, encodeId=3b1416553e75c, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Nov 14 05:28:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207962, encodeId=80cc20e9629d, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Jun 08 05:23:59 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=202163, encodeId=34ee20216379, content=新信号通路发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Wed May 24 23:48:27 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375573, encodeId=6f0813e557331, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat May 06 13:28:00 CST 2017, time=2017-05-06, status=1, ipAttribution=)]
    2017-05-06 jichang

相关资讯

Intens Care Med:感染性休克左室收缩功能障碍!

在大多数感染性休克患者中斑点追踪衍生的应变减少,揭示了隐匿性脓毒性心肌功能障碍,但其可行性较差。研究人员发现大部分的收缩性能指标与后负荷指数之间呈负相关。准确的后负荷评估在感染性休克患者左室收缩功能的充足解释中至关重要。

Am J Resp Crit Care:同时使用mRNA和蛋白生物标志物可以改善小儿感染性休克的危险分层!

由此可见,PERSEVERE-XP结合蛋白和mRNA的生物标志物可以提供死亡风险分层,具有可能的临床应用价值。PERSEVERE-XP比PERSEVERE具有显著的改善,并表明TP53相关细胞分裂、修复和代谢在感染性休克的病理生理机制中发挥着作用。

Crit Care:感染性休克患者不同种糖皮质激素治疗有差异吗?

由此可见,没有明确的证据表明任何一个皮质激素药物或治疗方案可能会比其他治疗更有效在降低死亡率、减少胃肠道出血或感染性休克二重感染方面。氢化可的松静脉注射或输液可能比安慰剂和甲基强的松龙更容易导致休克逆转。

Crit Care Med:多粘菌素B血液灌流对重症败血症和感染性休克患者死亡率的影响!

本荟萃分析结果表明,多粘菌素B血液灌流治疗可降低特定疾病严重程度子群的严重脓毒症和感染性休克患者死亡率。

NEJM:感染性休克患者早期靶向治疗效果如何?

在这项对个体病人数据进行的荟萃分析中,EGDT并不会比常规治疗产生更好的结局,并且与所有特点的患者和医院的较高住院费用有关。

Crit Care:各种糖皮质激素以及给药方案用于感染性休克的疗效有差别吗?

多种糖皮质激素和治疗方案用于感染性休克的辅助治疗,他们之间的患者结局有差异吗?2017年3月,发表在《Crit Care》的一项研究显示,无明确证据表明任何糖皮质激素药物或治疗方案在减少感染性休克的死亡率或降低胃肠出血或双重感染的发生率更有效。背景:多种糖皮质激素和治疗方案用于感染性休克的辅助治疗。不同药物及给药方式之间的细胞和组织水平存在定性和定量差异。本研究旨在阐明感染性休克成年患者中药物间及